Steven R. Feldman, MD, PhD, Linda S. Cox, MD, Lindsay C. Strowd, MD, Robert A. Gerber, PharmD, Steven Faulkner, PharmD, MBA, Debra Sierka, PharmD, Timothy W. Smith, BA, Joseph C. Cappelleri, PhD, Mark E. Levenberg, DO
Atopic dermatitis is a chronic inflammatory skin disease that is characterized by intense itch and acute, subacute, or chronic eczematous skin lesions. The disease course can be chronic or relapsingremitting. Lesions typically present with an age-related morphology and distribution.
Evolving Therapies for Atopic Dermatitis Will Create New Management Challenges
Can Academic Detailing Move the Needle for Patients with Diabetes in a State-Based Prescription Drug Benefit Program?
Academic detailing, a means of providing educational outreach to providers, has been described as a face-to-face interactive encounter between a healthcare provider and a clinical educator who is trained in social marketing and motivational interviewing skills to deliver actionable key messages in the privacy of providers’ offices.
Lana T. Al-Omar, PharmD, BCPS, Sarah L. Anderson, PharmD, FCCP, BCPS, BCACP, Amber D. Cizmic, PharmD, BCACP, Tara B. Vlasimsky, PharmD, BCPS, BCACP
Collaborative drug therapy management protocols are defined and written agreements between pharmacists and providers that allow pharmacists to optimize medication therapy management for individual patients.
Collaborative Efforts Help the Avoidance of Diabetes Mismanagement
Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis
Arijita Deb, PhD, Nilanjana Dwibedi, PhD, Traci LeMasters, PhD, Jo Ann Hornsby, MD, Wenhui Wei, PhD, Usha Sambamoorthi, PhD
Rheumatoid arthritis (RA) is a chronic systemic inflammatory condition that negatively affects the physical and mental health of individuals.
Comorbidities in Rheumatoid Arthritis Present Clinical, Economic Challenges for All Stakeholders
Pharmacist-Led Drug Therapy Problem Management in an Interprofessional Geriatric Care Continuum: A Subset of the PIVOTS Group
Ashley M. Campbell, PharmD, Kim C. Coley, PharmD, Jason M. Corbo, PharmD, Teresa M. DeLellis, PharmD, Matthew Joseph, PharmD, Carolyn T. Thorpe, PhD, MPH, Melissa S. McGivney, PharmD, Patricia Klatt, PharmD, Lora Cox-Vance, MD, Vincent Balestrino, MD, Heather Sakely, PharmD
Drug therapy problems, which are undesirable events that involve medications that can ultimately interfere with a patient’s therapeutic goals, are a major cause of morbidity, mortality, and hospitalizations in older adults.
Improving the Outcomes of Medication Use by Seniors
A Proposed Intervention to Decrease Resident-Performed Cataract Surgery Cancellation in a Tertiary Eye Care Center
Eileen L. Mayro, BA, Laura T. Pizzi, PharmD, MPH, Lisa A. Hark, PhD, RD, Ann P. Murchison, MD, MPH, Douglas Wisner, MD, Anish Koka, MD, Benjamin E. Leiby, PhD, Nooreen Dabbish, PhD, Adedoyin Okulate, BS, Alexa Dessy, BA, Caitlin Green, BS, Robert Bailey, MD
Yihua Xu, PhD, Lavanya Sudharshan, MS, Ming-Ann Hsu, MPH, Andrew S. Koenig, DO, FACR, Joseph C. Cappelleri, PhD, Wen F. Liu, PharmD, BCPS, Timothy W. Smith, BA, Margaret K. Pasquale, PhD
Avery A. Rizio, PhD, Michelle K. White, PhD, Kristen L. McCausland, MPH, PhD, Tiffany P. Quock, MS, PhD, Spencer D. Guthrie, MS, MBA, MPH, Miyo Yokota, PhD, Martha S. Bayliss, MS, MSc
Immunoglobulin light-chain amyloidosis (AL amyloidosis), one of the most common forms of amyloidosis, is a rare and typically fatal disease caused by misfolded light chains—protein chains formed by plasma cells that misfold into an abnormal shape—that form soluble toxic aggregates and deposit fibrils (amyloid) in organs.
Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia
Craig White, PhD, Winghan Jacqueline Kwong, PharmD, PhD, Hilary Armstrong, PhD, Michael Behling, Jeffrey Niemira, Kathy Lang, PhD
Preliminary results of this study were presented as a poster at the American Society of Health-System Pharmacists 2017 Summer Meetings and Exhibition.
Real-World Drug Prescribing and Utilization Studies Can Inform Optimized Patient Care and Insurance Coverage
Assessing the Level of Patient-Specific Treatment Recommendations in Clinical Practice Guidelines for Hemodialysis Vascular Access in the United States
In the United States, more than 80% of all patients with end-stage renal disease (ESRD) initiate dialysis with hemodialysis, and current reports indicate that this trend has changed little over the past 2 decades.
The Challenge of Maintaining Vascular Access in Patients with End-Stage Renal Disease
Page 1 of 13
Results 1 - 10 of 122
Results 1 - 10 of 122